Why Shares in Arcutis Biotherapeutics Surged Again This Week
Key Points
Arcutis aims to expand its market reach with new approvals.
Management recently pleased the market with its sales guidance for Zoryve.
- 10 stocks we like better than Arcutis Biotherapeutics ›
Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) continued their excellent run in 2025 (up 96%) with another 9.3% rise in the week to Friday morning. This week's move comes as the Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Arcutis' Zoryve (roflumilast) cream. The development raises confidence that the company will be able to extract full value from Zoryve across various indications.
Arcutis and Zoryve
Arcutis is a medical dermatology company with a commercialized therapy, Zoryve, approved for three inflammatory dermatoses: atopic dermatitis, seborrheic dermatitis, and plaque psoriasis. It's already approved in foam (better for hair-bearing areas) and cream (smooth areas), and in various concentrations, ranging from 0.3% to 0.05%.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
This week's news concerns the FDA's acceptance of an sNDA for Zoryve cream 0.3% for children aged two to five years with plaque psoriasis.
For reference, the pharmaceutical company has already obtained approval for Zoryve cream 0.3% to treat children aged 6 years and older with plaque psoriasis, and has also obtained approval for Zoryve 0.05% to treat children aged 2 to 5 years with atopic dermatitis. The FDA aims to complete the NDA review by June 29, 2026.
Image source: Getty Images.
Where next for Arcutis
The good news follows the recent excellent third-quarter results, which sent the stock soaring after management's sales outlook came in significantly ahead of market estimates, and Arcutis continues to try to expand the market potential for Zoryve.
Should you invest $1,000 in Arcutis Biotherapeutics right now?
Before you buy stock in Arcutis Biotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arcutis Biotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $593,222!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,143,342!*
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
